Monitoring Disease Activity and Progression in Crohn's Disease. A Swiss Perspective on the IBD Ahead ‘Optimised Monitoring' Recommendations

Abstract

Background and Aims: The structured IBD Ahead ‘Optimised Monitoring' programme was designed to obtain the opinion, insight and advice of gastroenterologists on optimising the monitoring of Crohn's disease activity in four settings: (1) assessment at diagnosis, (2) monitoring in symptomatic patients, (3) monitoring in asymptomatic patients, and (4) the postoperative follow-up. For each of these settings, four monitoring methods were discussed: (a) symptom assessment, (b) endoscopy, (c) laboratory markers, and (d) imaging. Based on literature search and expert opinion compiled during an international consensus meeting, recommendations were given to answer the question ‘which diagnostic method, when, and how often'. The International IBD Ahead Expert Panel advised to tailor this guidance to the healthcare system and the special prerequisites of each country. The IBD Ahead Swiss National Steering Committee proposes best-practice recommendations adapted for Switzerland. Methods: The IBD Ahead Steering Committee identified key questions and provided the Swiss Expert Panel with a structured literature research. The expert panel agreed on a set of statements. During an international expert meeting the consolidated outcome of the national meetings was merged into final statements agreed by the participating International and National Steering Committee members - the IBD Ahead ‘Optimized Monitoring' Consensus. Results: A systematic assessment of symptoms, endoscopy findings, and laboratory markers with special emphasis on faecal calprotectin is deemed necessary even in symptom-free patients. The choice of recommended imaging methods is adapted to the specific situation in Switzerland and highlights the importance of ultrasonography and magnetic resonance imaging besides endoscopy. Conclusion: The recommendations stress the importance of monitoring disease activity on a regular basis and by objective parameters, such as faecal calprotectin and endoscopy with detailed documentation of findings. Physicians should not rely on symptoms only and adapt the monitoring schedule and choice of options to individual situations.

Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn’s disease

“…An efficient therapeutic approach should aim to control tissue inflammation for mucosal healing and improve patient prognosis [8][9][10][11][12]. Frequent, objective, and regular evaluations of the inflammatory process are necessary to guide therapy [4,13].…”

Comparison of Small Bowel Lesions Using Capsule Endoscopy in Ulcerative Colitis and Crohn’s Disease: A Single-Center Retrospective Analysis

“…A large number of studies on small bowel lesions in CD using capsule endoscopy (CE) have clearly shown the superior diagnostic power of CE compared to other modalities [16, 17], as well as its usefulness in evaluation of disease activity [18, 19] and treatment selection [20, 21]. However, few studies have assessed UC small bowel lesions and none appear to have investigated the differences between these lesions in UC and CD.…”

New approaches in the follow-up of patients suffering from inflammatory bowel diseases

“…Apart from ileocolo noscopy, there are other endoscopic methods, such as capsule endoscopy or enteroscopy, which are important in cases, where ileocolonoscopy is in conclusive. Other imaging modalities, such as CT or MRI, play important role in disease extend and progression as sessment as well [16].…”